Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,180.74 +52.95 (+1.03%) Dow
38,852.27 +176.59 (+0.46%) Nasdaq
16,349.25 +192.92 (+1.19%) Bitcoin USD
63,514.45 -298.97 (-0.47%) CMC Crypto 200
1,364.74 +52.11 (+3.97%)
TFF Pharmaceuticals, Inc. (TFFP)
| Previous close | 2.0300 |
| Open | 2.0500 |
| Bid | 2.0500 x 100 |
| Ask | 2.3600 x 100 |
| Day's range | 1.9627 - 2.2899 |
| 52-week range | 1.9627 - 19.7500 |
| Volume | |
| Avg. volume | 35,325 |
| Market cap | 5.442M |
| Beta (5Y monthly) | 1.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.8500 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.50 |
GlobeNewswireTFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
FORT WORTH, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its previously announced public offering of an aggregate of 1,665,219 shares of its common stock (or common stock equivalents in lieu thereof) and warrants t
- GlobeNewswire
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the pricing of a public offering of an aggregate of 1,665,219 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 1,66
- GlobeNewswire
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
Data Now Available on Company Website Following 8-K Filing Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the Oral Tacrolimus Systemic Trough Exposures Gene Expression Biomarker Data Demonstrate that Treatment with TFF TAC Leads to Normalization of Expression of Rejection-Related Genes FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”)
